Literature DB >> 30864837

Targeting a fibrotic bottleneck may provide an opening in the treatment of LUTS.

William A Ricke1, Reginald C Bruskewitz1, Teresa T Liu1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30864837      PMCID： PMC6620586          DOI： 10.1152/ajprenal.00102.2019

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN： 1522-1466


× No keyword cloud information.
  11 in total

1.  Uropathogenic Escherichia coli induces chronic pelvic pain.

Authors:  Charles N Rudick; Ruth E Berry; James R Johnson; Brian Johnston; David J Klumpp; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

Review 2.  Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

Authors:  Claus G Roehrborn
Journal:  Med Clin North Am       Date:  2011-01       Impact factor: 5.456

3.  Collagen-targeted MRI contrast agent for molecular imaging of fibrosis.

Authors:  Peter Caravan; Biplab Das; Stéphane Dumas; Frederick H Epstein; Patrick A Helm; Vincent Jacques; Steffi Koerner; Andrew Kolodziej; Luhua Shen; Wei-Chuan Sun; Zhaoda Zhang
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

4.  Uropathogenic Escherichia coli-induced fibrosis, leading to lower urinary tract symptoms, is associated with type 2 cytokine signaling.

Authors:  Ashlee Bell-Cohn; Daniel J Mazur; Christel Hall; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Am J Physiol Renal Physiol       Date:  2019-01-09

5.  Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.

Authors:  Tristan M Nicholson; Priyanka D Sehgal; Sally A Drew; Wei Huang; William A Ricke
Journal:  Differentiation       Date:  2013-06-20       Impact factor: 3.880

Review 6.  Prostatic fibrosis, lower urinary tract symptoms, and BPH.

Authors:  Jose A Rodriguez-Nieves; Jill A Macoska
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

7.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

Authors:  John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin M Slawin; Joseph A Smith
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

Review 8.  The role of prostate inflammation and fibrosis in lower urinary tract symptoms.

Authors:  Wade A Bushman; Travis J Jerde
Journal:  Am J Physiol Renal Physiol       Date:  2016-07-20

9.  Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules.

Authors:  Tyler M Bauman; Tristan M Nicholson; Lisa L Abler; Kevin W Eliceiri; Wei Huang; Chad M Vezina; William A Ricke
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

10.  In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms.

Authors:  Ling Hao; Tyler Greer; David Page; Yatao Shi; Chad M Vezina; Jill A Macoska; Paul C Marker; Dale E Bjorling; Wade Bushman; William A Ricke; Lingjun Li
Journal:  Sci Rep       Date:  2016-08-09       Impact factor: 4.379
View more
  1 in total

1.  The anti-inflammation, anti-oxidative and anti-fibrosis properties of swertiamarin in cigarette smoke exposure-induced prostate dysfunction in rats.

Authors:  Jinglou Chen; Jianhua Liu; Yongfang Lei; Min Liu
Journal:  Aging (Albany NY)       Date:  2019-11-17       Impact factor: 5.682
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.